Retroperitoneal Lymph Node Dissection as Primary Treatment for Metastatic Seminoma
Reducing the long-term morbidity in testicular cancer survivors represents a major area of interest. External beam radiation therapy and systemic chemotherapy are established treatments for seminoma; however, they are associated with late toxicities such as cardiovascular disease, insulin resistance...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Advances in Urology |
| Online Access: | http://dx.doi.org/10.1155/2018/7978958 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556663034347520 |
|---|---|
| author | Brian Hu Siamak Daneshmand |
| author_facet | Brian Hu Siamak Daneshmand |
| author_sort | Brian Hu |
| collection | DOAJ |
| description | Reducing the long-term morbidity in testicular cancer survivors represents a major area of interest. External beam radiation therapy and systemic chemotherapy are established treatments for seminoma; however, they are associated with late toxicities such as cardiovascular disease, insulin resistance, and secondary malignancy. Retroperitoneal lymph node dissection (RPLND) is a standard treatment for nonseminomatous germ cell tumors (NSGCT) that has minimal long-term morbidity. Given the efficacy of RPLND in management of NSGCT, interest has developed in this surgery as a front-line treatment for seminoma with isolated lymph node metastasis to the retroperitoneum. Four retrospective studies have shown promising results when surgery is performed for seminomas with low-volume retroperitoneal metastases. To better determine if RPLND can be recommended as a primary treatment option, two prospective clinical trials (SEMS and PRIMETEST) are underway. This review will examine the literature, discuss the benefits/limitations of RPLND, and compare the methodologies of the two ongoing clinical trials. |
| format | Article |
| id | doaj-art-320db2f80d544cf0b6fbd7737da01be6 |
| institution | Kabale University |
| issn | 1687-6369 1687-6377 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Urology |
| spelling | doaj-art-320db2f80d544cf0b6fbd7737da01be62025-02-03T05:44:39ZengWileyAdvances in Urology1687-63691687-63772018-01-01201810.1155/2018/79789587978958Retroperitoneal Lymph Node Dissection as Primary Treatment for Metastatic SeminomaBrian Hu0Siamak Daneshmand1Department of Urology, Loma Linda University, 11234 Anderson Street Room A-560, Loma Linda, CA 92374, USAUniversity of Southern California Institute of Urology, 1441 Eastlake Avenue, Los Angeles, CA 90033, USAReducing the long-term morbidity in testicular cancer survivors represents a major area of interest. External beam radiation therapy and systemic chemotherapy are established treatments for seminoma; however, they are associated with late toxicities such as cardiovascular disease, insulin resistance, and secondary malignancy. Retroperitoneal lymph node dissection (RPLND) is a standard treatment for nonseminomatous germ cell tumors (NSGCT) that has minimal long-term morbidity. Given the efficacy of RPLND in management of NSGCT, interest has developed in this surgery as a front-line treatment for seminoma with isolated lymph node metastasis to the retroperitoneum. Four retrospective studies have shown promising results when surgery is performed for seminomas with low-volume retroperitoneal metastases. To better determine if RPLND can be recommended as a primary treatment option, two prospective clinical trials (SEMS and PRIMETEST) are underway. This review will examine the literature, discuss the benefits/limitations of RPLND, and compare the methodologies of the two ongoing clinical trials.http://dx.doi.org/10.1155/2018/7978958 |
| spellingShingle | Brian Hu Siamak Daneshmand Retroperitoneal Lymph Node Dissection as Primary Treatment for Metastatic Seminoma Advances in Urology |
| title | Retroperitoneal Lymph Node Dissection as Primary Treatment for Metastatic Seminoma |
| title_full | Retroperitoneal Lymph Node Dissection as Primary Treatment for Metastatic Seminoma |
| title_fullStr | Retroperitoneal Lymph Node Dissection as Primary Treatment for Metastatic Seminoma |
| title_full_unstemmed | Retroperitoneal Lymph Node Dissection as Primary Treatment for Metastatic Seminoma |
| title_short | Retroperitoneal Lymph Node Dissection as Primary Treatment for Metastatic Seminoma |
| title_sort | retroperitoneal lymph node dissection as primary treatment for metastatic seminoma |
| url | http://dx.doi.org/10.1155/2018/7978958 |
| work_keys_str_mv | AT brianhu retroperitoneallymphnodedissectionasprimarytreatmentformetastaticseminoma AT siamakdaneshmand retroperitoneallymphnodedissectionasprimarytreatmentformetastaticseminoma |